Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin for short-term cardiovascular events after myocardial infarction in type 2 diabetes
IRCT20210710051833N1Phase 3Completed
- Sponsor
- Zanjan University of Medical Sciences
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) and myocardial infarction (MI) comparing Empagliflozin with Placebo (2 arms). Primary endpoints: Short-term major cardiovascular events after myocardial infarction and Blood glucose level. Started Jul 2022; status: completed.
02
Drugs
empagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)myocardial infarction (MI)
Beyond the preview
Go deeper on IRCT20210710051833N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20210710051833N1.